@article{b4992fbdd8524de5831de106a54b808d,
title = "Metastasis-directed stereotactic radiotherapy for oligoprogressive castration-resistant prostate cancer: a multicenter study: World Journal of Urology",
abstract = "Purpose: Herein, we report the clinical outcomes of a multicenter study evaluating the role of SBRT in a cohort of patients affected by oligoprogressive castration-resistant prostate cancer (CRPC). Materials and methods: This is a retrospective multicenter observational study including eleven centers. Inclusion criteria of the current study were: (a) Karnofsky performance status > 80, (b) histologically proven diagnosis of PC, (c) 1–5 oligoprogressive metastases, defined as progressive disease at bone or nodes levels (detected by means of choline PET/CT or CT plus bone scan) during ADT, (d) serum testosterone level under 50 ng/ml during ADT, (e) controlled primary tumor, (f) patients treated with SBRT with a dose of at least 5 Gy per fraction to a biologically effective dose (BED) of at least 80 Gy using an alpha-to-beta ratio of 3 Gy, (g) at least 6 months of follow-up post-SBRT. Results: Eighty-six patients for a total of 117 lesions were treated with SBRT. The median follow-up was 30.7 months (range 4–91 months). The median new metastasis-free survival after SBRT was 12.3 months (95% CI 5.5–19.1 months). One- and two-year distant progression-free survival was 52.3% and 33.7%, respectively. Twenty-six out of 86 patients underwent a second course of SBRT due to further oligoprogressive disease: This resulted in a median systemic treatment-free survival of 21.8 months (95% CI 17.8–25.8 months). One-year systemic treatment-free survival was 72.1%. Conclusion: SBRT appears to be a promising approach in oligoprogressive castration-resistant prostate cancer. Further investigations are warranted. {\textcopyright} 2019, Springer-Verlag GmbH Germany, part of Springer Nature.",
keywords = "CRPC, Metastasis-directed therapy, Prostate cancer, Radiotherapy, SBRT",
author = "L. Triggiani and R. Mazzola and S.M. Magrini and G. Ingrosso and P. Borghetti and F. Trippa and A. Lancia and B. Detti and G. Francolini and F. Matrone and R. Bortolus and G. Fanetti and E. Maranzano and F. Pasqualetti and F. Paiar and M.L. Bon{\`u} and A. Magli and A. Bruni and E. Mazzeo and C. Franzese and M. Scorsetti and F. Alongi and B.A. Jereczek-Fossa and P. Ost and M. Buglione",
note = "Cited By :8 Export Date: 2 March 2020 Correspondence Address: Mazzola, R.; Radiation Oncology Department, IRCCS, Sacro Cuore Don Calabria HospitalItaly; email: rosariomazzola@hotmail.it References: Cornford, P., Bellmunt, J., Bolla, M., EAU-ESTRO-SIOG guidelines on prostate cancer. Part II: treatment of relapsing, metastatic, and castration resistant prostate cancer (2017) Eur Urol, 71, pp. 630-642; Tannock, I.F., de Wit, R., Berry, W.R., Docetaxel plus prednisone or mitoxantrone plus prednisone for advanced prostate cancer (2004) N Engl J Med, 351, pp. 1502-1512. , COI: 1:CAS:528:DC%2BD2cXot1Kmu7s%3D; Ryan, C.J., Smith, M.R., de Bono, J.S., Abiraterone in metastatic prostate cancer without previous chemotherapy (2013) N Engl J Med, 368, pp. 138-148. , COI: 1:CAS:528:DC%2BC3sXovVyhtw%3D%3D; Ryan, C.J., Smith, M.R., Fizazi, K., Abiraterone acetate plus prednisone versus placebo plus prednisone in chemotherapy-naive men with metastatic castration-resistant prostate cancer (COU-AA-302): final overall survival analysis of a randomised, double-blind, placebo-controlled phase 3 study (2015) Lancet Oncol, 16, pp. 152-160. , COI: 1:CAS:528:DC%2BC2MXhtFKntbo%3D; Beer, T.M., Armstrong, A.J., Rathkopf, D.E., Enzalutamide in metastatic prostate cancer before chemotherapy (2014) N Engl J Med, 371, pp. 424-433; de Bono, J.S., Logothetis, C.J., Molina, A., Abiraterone and increased survival in metastatic prostate cancer (2011) N Engl J Med, 364, pp. 1995-2005; Fizazi, K., Scher, H.I., Molina, A., Abiraterone acetate for treatment of metastatic castration-resistant prostate cancer: final overall survival analysis of the COU-AA-301 randomised, double-blind, placebo-controlled phase 3 study (2012) Lancet Oncol, 13, pp. 983-992. , COI: 1:CAS:528:DC%2BC38XhsVCjsbjK; Scher, H.I., Fizazi, K., Saad, F., Increased survival with enzalutamide in prostate cancer after chemotherapy (2012) N Engl J Med, 367, pp. 1187-1197. , COI: 1:CAS:528:DC%2BC38XhsVKhsLvK; Oudard, S., Fizazi, K., Sengel{\o}v, L., Cabazitaxel versus docetaxel as first-line therapy for patients with metastatic castration-resistant prostate cancer: a randomized phase III trial-FIRSTANA (2017) J Clin Oncol, 35, pp. 3189-3197. , COI: 1:CAS:528:DC%2BC1cXitVemu73L; Triggiani, L., Alongi, F., Buglione, M., Efficacy of stereotactic body radiotherapy in oligorecurrent and in oligoprogressive prostate cancer: new evidence from a multicentric study (2017) Br J Cancer, 116, pp. 1520-1525; Ost, P., Bossi, A., Decaestecker, K., Metastasis-directed therapy of regional and distant recurrences after curative treatment of prostate cancer: a systematic review of the literature (2015) Eur Urol, 67, pp. 852-863; Fanetti, G., Marvaso, G., Ciardo, D., Stereotactic body radiotherapy for castration-sensitive prostate cancer bone oligometastases (2018) Med Oncol, 35, p. 75; Ponti, E., Lancia, A., Ost, P., Exploring all avenues for radiotherapy in oligorecurrent prostate cancer disease limited to lymph nodes: a systematic review of the role of stereotactic body radiotherapy (2017) Eur Urol Focus, 3 (6), pp. 538-544; Jereczek-Fossa, B.A., Beltramo, G., Robotic image-guided stereotactic radiotherapy, for isolated recurrent primary, lymph node or metastatic prostate cancer (2012) Int J Radiat Oncol Biol Phys, 82, pp. 889-897; Decaestecker, K., De Meerleer, G., Lambert, B., Repeated stereotactic body radiotherapy for oligometastatic prostate cancer recurrence (2014) Radiat Oncol, 9, p. 135; Ost, P., Reynders, D., Decaestecker, K., Surveillance or metastasis directed therapy for oligometastatic prostate cancer recurrence: a prospective, randomized, multicenter phase II trial (2018) J Clin Oncol, 36, pp. 446-453. , COI: 1:CAS:528:DC%2BC1cXitFOqt7jJ; De Bruycker, A., Lambert, B., Claeys, T., Prevalence and prognosis of low-volume, oligorecurrent, hormone-sensitive prostate cancer amenable to lesion ablative therapy (2017) BJU Int, 120, pp. 815-821; Wahl, R.L., Jacene, H., Kasamon, Y., From RECIST to PERCIST: evolving considerations for PET response criteria in solid tumors (2009) J Nucl Med, 50, pp. 122S-150S. , COI: 1:CAS:528:DC%2BD1MXmtFahtr8%3D; Harris, W.P., Mostaghel, E.A., Nelson, P.S., Androgen deprivation therapy: progress in understanding mechanisms of resistance and optimizing androgen depletion (2009) Nat Clin Pract Urol, 6, pp. 76-85. , COI: 1:CAS:528:DC%2BD1MXhsFenu7Y%3D; Boev{\'e}, L.M.S., Hulshof, M.C.C.M., Vis, A.N., Effect on survival of androgen deprivation therapy alone compared to androgen deprivation therapy combined with concurrent radiation therapy to the prostate in patients with primary bone metastatic prostate cancer in a prospective randomised clinical trial: data from the HORRAD trial (2018) Eur Urol, 75, pp. 410-418; Parker, C.C., James, N.D., Brawley, C.D., Radiotherapy to the primary tumour for newly diagnosed, metastatic prostate cancer (STAMPEDE): a randomised controlled phase 3 trial (2018) Lancet, 392 (10162), pp. 2353-2366; Palma, D.A., Haasbeek, C.J., Rodrigues, G.B., Stereotactic ablative radiotherapy for comprehensive treatment of oligometastatic tumors (SABR-COMET): study protocol for a randomized phase II trial (2012) BMC Cancer, 12, p. 305. , COI: 1:CAS:528:DC%2BC38Xhs1SisbjF; Mazzola, R., Fersino, S., Ferrera, G., Stereotactic body radiotherapy for lung oligometastases impacts on systemic treatment-free survival: a cohort study (2018) Med Oncol, 35 (9), p. 121; Correa, R.J., Salama, J.K., Milano, M.T., Stereotactic body radiotherapy for oligometastasis: opportunities for biology to guide clinical management (2016) Cancer J, 22 (4), pp. 247-256. , COI: 1:CAS:528:DC%2BC28Xht1CjsrfN; Ost, P., Jereczek-Fossa, B.A., Van As, N., Zilli, T., Pattern of progression after stereotactic body radiotherapy for oligometastatic prostate cancer nodal recurrences (2016) Clin Oncol (R Coll Radiol), 28, pp. e115-e120. , COI: 1:STN:280:DC%2BC28bltFWjsw%3D%3D; De Bari, B., Alongi, F., Lestrade, L., Giammarile, F., Choline-PET in prostate cancer management: the point of view of the radiation oncologist (2014) Crit Rev Oncol Hematol, 91 (3), pp. 234-247; Alongi, F., Fersino, S., Giaj Levra, N., Impact of 18F-choline PET/CT in the decision-making strategy of treatment volumes in definitive prostate cancer volumetric modulated radiation therapy (2015) Clin Nucl Med, 40 (11), pp. e496-e500",
year = "2019",
doi = "10.1007/s00345-019-02717-7",
language = "English",
volume = "37",
pages = "2631--2637",
journal = "World J. Urol.",
issn = "0724-4983",
publisher = "Springer Verlag",
number = "12",
}